FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...

Carotuximab (ENV105) plus standard-of-care hormone therapy apalutamide (Erleada) demonstrated a progression-free survival ...

ADG126 is a novel anti–CTLA-4 agent incorporating protease-cleavable masking technology that enables tumor-specific ...

Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...

Sacituzumab govitecan is comprised of a humanized antitrophoblast cell-surface antigen 2 monoclonal antibody coupled to SN-38 ...

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.

Through a search of electronic health records from the IKnowMed clinical oncology database (McKesson, Houston, TX, USA) the ...

In recognition of September as Prostate Cancer Awareness Month, Daniel Petrylak, MD, professor of oncology and urology at ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Plixorafenib (FORE 8394; PLX8394) with or without cobicistat (Tybost) demonstrated a clinical benefit and differentiated duration of response in patients with MAPK inhibitor-naive thyroid cancer ...

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma. The FDA has approved Bosaya and Aukelso (denosumab-kyqq) ...